Search

Your search keyword '"Valenti, Luca"' showing total 246 results

Search Constraints

Start Over You searched for: Author "Valenti, Luca" Remove constraint Author: "Valenti, Luca" Topic fatty liver Remove constraint Topic: fatty liver
246 results on '"Valenti, Luca"'

Search Results

1. Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD.

2. The first MASH drug therapy on the horizon: Current perspectives of resmetirom.

3. Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population.

4. Reproducibility and accuracy of a pocket-size ultrasound device in assessing liver steatosis.

5. Predictors of controlled attenuation parameter in metabolic dysfunction.

6. IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids.

8. A novel gene signature to diagnose MASLD in metabolically unhealthy obese individuals.

12. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals.

14. Reply to: "Lack of hepatic autophagy promotes severity of liver injury but not steatosis": ATG7 genetic variants behave as fatty liver disease progression modifiers.

15. PSD3 downregulation confers protection against fatty liver disease.

16. Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver.

17. The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation.

18. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.

19. Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD.

20. Genetic variants in the MTHFR are not associated with fatty liver disease.

21. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.

22. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.

24. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis.

25. Reply.

26. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.

27. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant.

28. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.

30. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.

31. Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease.

32. PNPLA3 I148M polymorphism and progressive liver disease.

33. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.

34. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease.

35. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.

36. PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease.

37. A 360-degree overview of paediatric NAFLD: recent insights.

38. Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis.

39. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.

40. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease.

41. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.

42. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease.

43. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease.

44. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.

45. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease.

48. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.

49. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.

50. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease.

Catalog

Books, media, physical & digital resources